Natera, Inc. $NTRA Shares Purchased by NWI Management LP

Key Points

• NWI Management LP increased its stake in Natera, Inc. by 12.5%, acquiring an additional 90,000 shares, making it the largest position in their investment portfolio.
• Natera reported a revenue of $546.60 million for the last quarter, exceeding estimates, but posted a loss of ($0.74) EPS, missing the consensus estimate.
• Insiders have sold a total of 52,344 shares in the last ninety days, indicating potential shifts in confidence, while institutional investors own 99.90% of the company’s stock.

NWI Management LP grew its holdings in Natera, Inc. (NASDAQ:NTRA - Free Report) by 12.5% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 810,000 shares of the medical research company's stock after purchasing an additional 90,000 shares during the quarter. Natera accounts for about 14.4% of NWI Management LP's holdings, making the stock its biggest holding. NWI Management LP owned about 0.60% of Natera worth $114,542,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in NTRA. LRI Investments LLC purchased a new position in shares of Natera in the fourth quarter valued at approximately $29,000. Bank of Jackson Hole Trust purchased a new stake in shares of Natera during the first quarter worth $29,000. Rakuten Securities Inc. increased its position in shares of Natera by 117.8% during the first quarter. Rakuten Securities Inc. now owns 220 shares of the medical research company's stock worth $31,000 after acquiring an additional 119 shares during the period. ORG Partners LLC purchased a new stake in shares of Natera during the first quarter worth $32,000. Finally, TCTC Holdings LLC increased its position in shares of Natera by 114.8% during the first quarter. TCTC Holdings LLC now owns 232 shares of the medical research company's stock worth $33,000 after acquiring an additional 124 shares during the period. Hedge funds and other institutional investors own 99.90% of the company's stock.

Natera Stock Performance

NTRA stock traded up $1.46 during midday trading on Friday, reaching $168.02. 776,006 shares of the company were exchanged, compared to its average volume of 1,058,112. Natera, Inc. has a 1-year low of $110.57 and a 1-year high of $183.00. The stock's 50-day simple moving average is $154.35 and its 200 day simple moving average is $153.68. The company has a market cap of $23.06 billion, a price-to-earnings ratio of -87.97 and a beta of 1.68.

Natera (NASDAQ:NTRA - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The medical research company reported ($0.74) earnings per share for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.14). Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.The company had revenue of $546.60 million for the quarter, compared to analyst estimates of $476.84 million. During the same period in the previous year, the business posted ($0.30) EPS. The firm's revenue for the quarter was up 32.2% compared to the same quarter last year. Natera has set its FY 2025 guidance at EPS. On average, research analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current year.

Insider Activity at Natera

In other Natera news, Director Rowan E. Chapman sold 2,750 shares of the firm's stock in a transaction that occurred on Thursday, August 28th. The shares were sold at an average price of $166.99, for a total transaction of $459,222.50. Following the sale, the director owned 6,015 shares of the company's stock, valued at approximately $1,004,444.85. This trade represents a 31.37% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Solomon Moshkevich sold 3,000 shares of the firm's stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $166.62, for a total transaction of $499,860.00. Following the sale, the insider directly owned 120,859 shares in the company, valued at approximately $20,137,526.58. The trade was a 2.42% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 55,344 shares of company stock valued at $8,271,610 in the last quarter. Company insiders own 5.63% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the company. Stephens reaffirmed an "overweight" rating and set a $183.00 price objective on shares of Natera in a research report on Friday, August 15th. Royal Bank Of Canada set a $268.00 price objective on Natera and gave the stock an "outperform" rating in a research report on Tuesday, September 2nd. Evercore ISI raised Natera to a "strong-buy" rating and set a $170.00 price objective on the stock in a research report on Monday, July 28th. Wall Street Zen cut shares of Natera from a "hold" rating to a "sell" rating in a report on Saturday, May 17th. Finally, Morgan Stanley reaffirmed an "overweight" rating and issued a $195.00 target price on shares of Natera in a report on Sunday, August 10th. One equities research analyst has rated the stock with a Strong Buy rating and seventeen have issued a Buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $194.00.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.